SCHEMBL20487579

SCHEMBL20487579

CCOC(=O)C(OCc1ccccc1)C1(O)CCNCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.49
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TLR2 O60603 2/20 0.39
TACR1 P25103 1/20 0.39
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
SLC1A3 P43003 2/20 0.39
SLC1A2 P43004 2/20 0.39
SLC1A1 P43005 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
PPID Q08752 1/20 0.39
MMP8 P22894 1/20 0.39
ALDH1A1 P00352 1/20 0.38
ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22893595 0.78 GPR119 (0.46) L3MBTL1TACR1CYP1A2CYP2C9ALDH1A1
SCHEMBL20487576 0.78 GPR119 (0.46) L3MBTL1TACR1CYP1A2CYP2C9ALDH1A1
SCHEMBL22893643 0.77 OPRM1 (0.51) OPRM1LMNAL3MBTL1CYP2D6MMP8
SCHEMBL22893594 0.76 ALDH1A1 (0.45) OPRM1L3MBTL1TLR2TACR1DDB1
SCHEMBL28415658 0.75 TYR (0.42) LMNAL3MBTL1DDB1CRBNSLC1A3
Hydrochloric Acid SCHEMBL20487582 0.75 DDB1 (0.44) OPRM1L3MBTL1TLR2TACR1DDB1
SCHEMBL23813082 0.73 LMNA (0.50) OPRM1LMNAL3MBTL1TACR1DDB1
SCHEMBL8329550 0.72 L3MBTL1 (0.54) LMNAL3MBTL1SLC1A3SLC1A2SLC1A1
SCHEMBL9532125 0.72 KMT2A (0.56) LMNAL3MBTL1SLC1A3SLC1A2SLC1A1
SCHEMBL6522997 0.71 OPRM1 (0.56) OPRM1LMNATACR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223289-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN SCHRODINGER, INC. 2025-07-10 US disclosed
US-12145935-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2024-11-19 US disclosed
US-20240116929-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2024-04-11 US disclosed
US-11795167-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-10-24 US disclosed
US-11795167-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-10-24 US disclosed
US-11795167-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-10-24 US disclosed
EP-4147698-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Morphic Therapeutic, Inc. (US) 2023-03-15 EP disclosed
US-20210284640-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Lazuli, Inc. 2021-09-16 US disclosed
US-20210284640-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Lazuli, Inc. 2021-09-16 US disclosed
US-11046685-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-29 US disclosed
US-11046685-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-29 US disclosed
EP-3760202-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Morphic Therapeutic, Inc. (US) 2021-01-06 EP disclosed
EP-3760202-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Morphic Therapeutic, Inc. (US) 2021-01-06 EP disclosed
WO-2018160522-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Lazuli, Inc. (US) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046685-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV OPRM1 1773/4885LMNA 2270/4885L3MBTL1 1323/4885
US-20250223289-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV OPRM1 1741/4885LMNA 1894/4885L3MBTL1 1149/4885
US-20210284640-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV OPRM1 1741/4885LMNA 1894/4885L3MBTL1 1149/4885
US-12145935-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV OPRM1 1848/4885LMNA 2182/4885L3MBTL1 1156/4885
US-11795167-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV OPRM1 1848/4885LMNA 2182/4885L3MBTL1 1156/4885
US-20240116929-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV OPRM1 1741/4885LMNA 1894/4885L3MBTL1 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.